JP2019088334A5 - - Google Patents

Download PDF

Info

Publication number
JP2019088334A5
JP2019088334A5 JP2019052699A JP2019052699A JP2019088334A5 JP 2019088334 A5 JP2019088334 A5 JP 2019088334A5 JP 2019052699 A JP2019052699 A JP 2019052699A JP 2019052699 A JP2019052699 A JP 2019052699A JP 2019088334 A5 JP2019088334 A5 JP 2019088334A5
Authority
JP
Japan
Prior art keywords
cells
hla
genetically modified
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019052699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019088334A (ja
JP7294838B2 (ja
Filing date
Publication date
Priority claimed from JP2018028816A external-priority patent/JP6502544B2/ja
Application filed filed Critical
Publication of JP2019088334A publication Critical patent/JP2019088334A/ja
Publication of JP2019088334A5 publication Critical patent/JP2019088334A5/ja
Priority to JP2021068195A priority Critical patent/JP7379410B2/ja
Application granted granted Critical
Publication of JP7294838B2 publication Critical patent/JP7294838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019052699A 2012-07-31 2019-03-20 Hla g改変された細胞および方法 Active JP7294838B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021068195A JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261677739P 2012-07-31 2012-07-31
US61/677,739 2012-07-31
JP2018028816A JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018028816A Division JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021068195A Division JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Publications (3)

Publication Number Publication Date
JP2019088334A JP2019088334A (ja) 2019-06-13
JP2019088334A5 true JP2019088334A5 (enExample) 2019-09-26
JP7294838B2 JP7294838B2 (ja) 2023-06-20

Family

ID=50028654

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015525519A Active JP6297559B2 (ja) 2012-07-31 2013-07-30 Hlag改変された細胞および方法
JP2018028816A Active JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法
JP2019052699A Active JP7294838B2 (ja) 2012-07-31 2019-03-20 Hla g改変された細胞および方法
JP2021068195A Active JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015525519A Active JP6297559B2 (ja) 2012-07-31 2013-07-30 Hlag改変された細胞および方法
JP2018028816A Active JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021068195A Active JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Country Status (10)

Country Link
US (4) US9714280B2 (enExample)
EP (4) EP2880054B1 (enExample)
JP (4) JP6297559B2 (enExample)
KR (4) KR102366081B1 (enExample)
CN (2) CN105612176B (enExample)
AU (2) AU2013296564C1 (enExample)
CA (1) CA2882028C (enExample)
ES (2) ES2716577T3 (enExample)
SG (1) SG11201500799YA (enExample)
WO (1) WO2014022423A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2699593T4 (da) 2011-04-20 2021-02-08 Univ Washington Through Its Center For Commercialization Beta-2 mikroglobulin-deficiente celler
EP4253409A3 (en) 2012-04-17 2023-12-06 University of Washington through its Center for Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
HUE052552T2 (hu) 2014-04-09 2021-05-28 Dna Twopointo Inc Javított nukleinsav-konstrukciók eukarióta génexpresszióhoz
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
GB2548059B (en) * 2014-11-26 2020-09-02 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2017058819A1 (en) 2015-10-02 2017-04-06 The Regents Of The University Of California Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
US20220241345A1 (en) * 2015-10-02 2022-08-04 The Regents Of The University Of California Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
LT3359671T (lt) 2015-10-08 2021-12-10 Dna Twopointo Inc. Dnr vektoriai, transpozonai ir transpozazės, skirti eukariotinio genomo modifikacijai
CA3027428A1 (en) * 2016-06-14 2017-12-21 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
AU2017301705A1 (en) 2016-07-26 2019-01-24 North Carolina State University Vector-mediated immune tolerance in the eye
AU2018208614A1 (en) * 2017-01-10 2019-07-11 The General Hospital Corporation Modified T cells and methods of their use
CN110869494B (zh) * 2017-06-12 2025-02-18 西奈卫生系统公司 无需全身性免疫遏制的同种异体移植物耐受
AU2018395397A1 (en) * 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
KR102907902B1 (ko) * 2018-08-01 2026-01-02 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
CA3123102A1 (en) 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
MX2021006773A (es) * 2018-12-14 2021-09-21 Promethera Therapeutics Sa Composicion celular que comprende celulas progenitoras del higado que expresan hla-e.
WO2020120666A1 (en) 2018-12-14 2020-06-18 Promethera Biosciences S.A./N.V. Liver progenitor cells expressing hla-g, and method for obtaining these cells compositions comprising said cells and their use
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
EP4103696A1 (en) * 2020-02-10 2022-12-21 Rubius Therapeutics, Inc. Engineered erythroid cells including hla-g polypeptides and methods of use thereof
US20230203445A1 (en) * 2020-05-26 2023-06-29 Healios K.K. Hypoimmunogenic cells
CN114746152A (zh) * 2020-08-23 2022-07-12 应用干细胞有限公司 Hla-f修饰的细胞和方法
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
CN113234664B (zh) * 2021-05-11 2024-05-10 澳门大学 一种胰腺祖细胞的制备方法及其应用
JP2024540987A (ja) * 2021-10-21 2024-11-06 バーテックス ファーマシューティカルズ インコーポレイテッド 低免疫細胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5534423A (en) 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5744320A (en) 1995-06-07 1998-04-28 Promega Corporation Quenching reagents and assays for enzyme-mediated luminescence
US6982431B2 (en) 1998-08-31 2006-01-03 Molecular Devices Corporation Sample analysis systems
US6031094A (en) 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
JP4070611B2 (ja) 2001-04-23 2008-04-02 アマクサ アーゲー 電気穿孔法用の緩衝溶液およびその使用を含む方法
US7763466B2 (en) 2002-05-17 2010-07-27 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
KR20050109934A (ko) 2003-01-31 2005-11-22 프로메가 코포레이션 관능기의 단백질로의 공유 테더링
US7960166B2 (en) 2003-05-21 2011-06-14 The General Hospital Corporation Microfabricated compositions and processes for engineering tissues containing multiple cell types
CA2541523A1 (en) * 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
BRPI0517380A (pt) 2004-11-08 2008-10-07 Chromagenics Bv molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CN101330935B (zh) * 2005-10-21 2013-11-13 细胞研究私人有限公司 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
WO2007087539A2 (en) * 2006-01-24 2007-08-02 The University Of Chicago Snp binding site for micrornas in hla-g
WO2007091078A2 (en) * 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
EP2374875B1 (en) 2006-10-30 2015-09-02 Promega Corporation Mutant hydrolase proteins with enhanced kinetics and funcitional expression
US8647871B2 (en) * 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
JP2012508591A (ja) * 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション 細胞を操作するための組成物および方法
US8592211B2 (en) 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
CN103333861A (zh) * 2013-06-03 2013-10-02 浙江省台州医院 特异性表达hla-g1抗原的细胞株k562
CN111808819A (zh) * 2020-05-26 2020-10-23 台州恩泽医疗中心(集团) 表达hla-g3异构体标准蛋白的细胞株及其应用

Similar Documents

Publication Publication Date Title
JP2015529457A5 (enExample)
JP6502544B2 (ja) Hla g改変された細胞および方法
ES2601845T3 (es) Aislamiento y purificación de células madre hematopoyéticas a partir de lipoaspirados post-liposucción
JP2021534806A (ja) ユニバーサルドナー細胞
JP2020509780A (ja) 細胞並びにその使用方法及び製造方法
JP7016556B2 (ja) 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途
JP2022539496A (ja) 安全な免疫ステルス細胞
EP3831945A1 (en) Protein heterodimer and use thereof
US20230235280A1 (en) Modified stem cells and methods of use thereof
JP2022551478A (ja) 持続的トランスジーン発現を伴う細胞
Lim et al. Microporation is a valuable transfection method for efficient gene delivery into human umbilical cord blood-derived mesenchymal stem cells
JP2024535677A5 (enExample)
JP2021522837A (ja) 造血幹細胞移植のための組成物及び方法
CN117716026A (zh) 具有氧化应激抗性的间充质干细胞、其制备方法及用途
WO2016112779A1 (en) Modified cells evoking reduced immunogenic responses
JP2021503008A (ja) 造血幹細胞および前駆細胞移植療法のための組成物および方法
JP5745419B2 (ja) 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法
JP6691756B2 (ja) 合成ペプチドを用いた神経幹細胞の生産方法
CN120615119A (zh) 用于同种异体细胞疗法以覆盖全球、种族或特定疾病群体的免疫相容细胞
US20230242894A1 (en) Novel transplantation cells having reduced immunogenicity
CN116396940A (zh) 造血干祖细胞及其制备方法和用途
JP7144829B2 (ja) 安全性と抗炎症作用を高めた間葉系幹細胞
Carretero et al. Applicability of bioengineered human skin: from preclinical skin humanized mouse models to clinical regenerative therapies
Sennikov et al. Dendritic Cells Transfected with MHC Antigenic Determinants of CBA Mice Induce Antigen‐Specific Tolerance in C57Bl/6 Mice
CN100408677C (zh) 一种bdnf基因修饰的间充质干细胞的构建方法